title: Implanted bisphosphonates in bone cement affect bone markers in rat serum.
abstract: OBJECTIVE
  Bisphosphonates (BPs) are antiresorptive drugs that provide important effects on bone turnover. The key to the high efficiency of BPs is their affinity for bone tissue, and their chemical structure provides their molecular mechanism of action. BPs are widely used to treat a variety of diseases that cause excess bone resorption, such as bone metastasis, hypercalcaemia due to malignancy and Paget's disease. The goal of this study was to assess whether the bisphosphonate (Pamifos®) present in bone cement has any effect on bone turnover. In this paper, we present changes in cytokine levels in the serum of rats treated surgically.
  
  
  METHODS
  Research was performed on 40 adult male Wistar rats. The rats were divided into four groups: two control groups (A, B) and two experimental groups (C, D). Bone in rats in the experimental groups was implanted with BP-enriched cement, whereas bone in control-groups rats was implanted with clean cement (without BPs).
  
  
  RESULTS
  We found a higher concentration of tumour necrosis factor alpha (TNF-α) three weeks after surgery in rats implanted with BP-enriched cement compared with rats implanted with clean cement. After six weeks of treatment, TNF-α levels decreased significantly in rats treated with BP-enriched cement, whereas the control group experienced an increase in TNF-α. The concentration of osteoprotegerin ligand (OPG) was higher in rats with BP implants. We found high levels of receptor activator of nuclear factor kappa-B ligand (RANKL) in rats after implantation of cement without BP in both groups.
  
  
  CONCLUSIONS
  We conclude that use of bisphosphonate (Pamifos®), which is present in bone cement, has an effect on bone turnover in that BPs stimulate an increase in OPG and a decrease in RANKL in the bone microenvironment and thus may be an important component of mechanisms that reduce bone resorption. Therefore, the use of BP-enriched cement implants appears to be justified.
authors: Orthopedic and Traumatology Department, Medical University of Lublin, Lublin, Poland.
authors: Tomasz
authors: T
authors: Mazurkiewicz
authors: Lukasz
authors: L
authors: Matuszewski
authors: Anna
authors: A
authors: Matuszewska
authors: Magdalena
authors: M
authors: Jaszek
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D001843:Bone Cements; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001862:Bone Resorption / Q000188:drug therapy*; D004164:Diphosphonates / Q000494:pharmacology*; D008297:Male; D053245:RANK Ligand / Q000097:blood*; D051381:Rats; D017208:Rats, Wistar; D013977:Tibia / Q000187:drug effects / Q000293:injuries; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D015415:Biomarkers; D001843:Bone Cements; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha
references: J Lipid Res. 1992 Nov;33(11):1657-63
references: 1464749
references: J Pharmacol Exp Ther. 1996 May;277(2):1097-102
references: 8627521
references: Acta Orthop Scand. 2002 Jan;73(1):20-3
references: 11928906
references: Pol Merkur Lekarski. 2008 Jul;25(145):57-60
references: 18839616
references: Arthritis Res Ther. 2006;8(1):201
references: 16356195
references: Acta Orthop Scand. 2002 Jan;73(1):24-30
references: 11928907
references: Br J Cancer. 2001 Apr 6;84(7):951-8
references: 11286476
references: J Immunol. 2004 Oct 15;173(8):4838-46
references: 15470024
references: Bone. 1996 Jan;18(1):9-14
references: 8717530
references: Mol Pharmacol. 1999 Jul;56(1):131-40
references: 10385693
references: Bone. 1998 May;22(5):455-61
references: 9600778
references: Bone. 2011 Jul;49(1):95-102
references: 21256254
references: N Engl J Med. 1990 Jul 12;323(2):73-9
references: 2113611
references: J Bone Miner Res. 1997 Sep;12(9):1358-67
references: 9286751
references: J Biol Chem. 2001 Jan 5;276(1):563-8
references: 11032840
references: Endocr Rev. 1998 Feb;19(1):80-100
references: 9494781
references: Bone. 1995 Aug;17(2 Suppl):87S-91S
references: 8579904
references: Genes Dev. 1998 May 1;12(9):1260-8
references: 9573043
references: Cell. 1997 Apr 18;89(2):309-19
references: 9108485
references: Bone. 2006 Aug;39(2):325-35
references: 16580896
references: Am J Pathol. 2000 Aug;157(2):435-48
references: 10934148
references: Lancet. 1980 May 17;1(8177):1043-7
references: 6103389
references: J Clin Invest. 1993 May;91(5):2004-11
references: 8486770
references: Endocrinology. 2001 Dec;142(12):5050-5
references: 11713196
references: Biochem Biophys Res Commun. 2002 Mar 1;291(3):680-6
references: 11855844
references: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5
references: 10097072
references: N Engl J Med. 1998 Aug 6;339(6):398-400
references: 9691109
references: Cancer Res. 2000 Nov 1;60(21):6001-7
references: 11085520
references: Endocrinology. 1996 Jun;137(6):2324-33
references: 8641182
references: Curr Mol Med. 2001 Jul;1(3):317-24
references: 11899080
references: Biochem Biophys Res Commun. 2000 Aug 2;274(2):281-90
references: 10913332
references: Curr Opin Immunol. 2000 Jun;12(3):316-22
references: 10781406
references: J Cell Biochem. 1998 Feb 1;68(2):186-94
references: 9443074
references: Bone. 1999 Jul;25(1):97-106
references: 10423031
references: Acta Orthop Scand. 2003 Aug;74(4):483-9
references: 14521303
references: J Clin Invest. 2005 Feb;115(2):282-90
references: 15668736
references: N Engl J Med. 1998 Jul 30;339(5):292-9
references: 9682041